Outcomes of Redo Transcatheter Aortic Valve Replacement for the Treatment of Postprocedural and Late Occurrence of Paravalvular Regurgitation and Transcatheter Valve Failure.

نویسندگان

  • Marco Barbanti
  • John G Webb
  • Claudia Tamburino
  • Nicolas M Van Mieghem
  • Raj R Makkar
  • Nicolò Piazza
  • Azeem Latib
  • Jan-Malte Sinning
  • Kim Won-Keun
  • Sabine Bleiziffer
  • Francesco Bedogni
  • Samir Kapadia
  • Didier Tchetche
  • Josep Rodés-Cabau
  • Claudia Fiorina
  • Luis Nombela-Franco
  • Federico De Marco
  • Peter P de Jaegere
  • Tarun Chakravarty
  • Beatriz Vaquerizo
  • Antonio Colombo
  • Lars Svensson
  • Rüdiger Lange
  • Georg Nickenig
  • Helge Möllmann
  • Thomas Walther
  • Francesco Della Rosa
  • Yacine Elhmidi
  • Danny Dvir
  • Nedy Brambilla
  • Sebastiano Immè
  • Carmelo Sgroi
  • Simona Gulino
  • Denise Todaro
  • Gerlando Pilato
  • Anna Sonia Petronio
  • Corrado Tamburino
چکیده

BACKGROUND Transcatheter aortic valves can degenerate in a manner similar to surgical bioprostheses. METHODS AND RESULTS Clinical and echocardiographic outcomes of patients who underwent redo transcatheter aortic valve replacement (TAVR) procedures >2 weeks post procedure were collected from 14 centers. Among 13 876 patients, 50 (0.4%) underwent redo TAVR procedure at participating centers. Indications for redo TAVR were moderate-severe prosthetic aortic valve stenosis (n=10, 21.7%), moderate-severe central prosthetic aortic valve regurgitation (n=13, 28.3%), and moderate-severe paraprosthetic aortic valve regurgitation (n=25, 50.0%). The index TAVR was most commonly a Medtronic CoreValve (N=38, 76.0%), followed by Edwards SAPIEN-type valves (n=12, 24.0%) and Portico (n=1, 2.0%). The redo TAVR device was most commonly a CoreValve/Evolut R (n=29, 58.0%), followed by a SAPIEN-type valve (n=20,40.0%) or a Boston Lotus valve (n=1, 2.0%). In 40 patients (80.0%), redo TAVR was performed using the identical device type or that of the succeeding generation. Valve performance was uniformly good after redo TAVR (mean transvalvular gradient post redo TAVR: 12.5±6.1 mm Hg). At hospital discharge, all patients remained alive, with 1 nondisabling stroke (2.0%) and 1 life-threatening bleed (2.0%). Permanent pacemaker implantation was required in 3 out of 35 patients without a prior pacemaker (8.6%). Late survival was 85.1% at a median follow-up of 1589 days (range: 31-3775) after index TAVR and 635 days (range: 8-2460) after redo TAVR. CONCLUSIONS Redo TAVR for the treatment of postprocedural and late occurrence of paravalvular regurgitation and transcatheter aortic valve prosthesis failure seems to be safe, and it is associated with favorable acute and midterm clinical and echocardiographic outcomes.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Transcatheter Aortic Valve Replacement: A Review Article

Transcatheter aortic valve replacement (TAVR) is a novel therapeutic intervention for the replacement of severely stenotic aortic valves in high-risk patients for standard surgical procedures. Since the initial PARTNER trial results, use of TAVR has been on the rise each year. New delivery methods and different valves have been developed and modified in order to promote the minimally invasive p...

متن کامل

Quantitative assessment of paravalvular regurgitation following transcatheter aortic valve replacement

Paravalvular regurgitation (PVR) following transcatheter aortic valve replacement is a known complication associated with poorer outcomes. This article discusses the current techniques for assessing the severity of PVR, including angiography, hemodynamics, MRI, and echocardiography. The strengths and pitfalls of each modality are reviewed.

متن کامل

High-risk Coronary Artery Bypass Grafting and Mitral Valve Replacement in a HIV Positive Patient

Certain subsets of high-risk mitral valve patients are not suitable candidates for transcatheter therapies. The objective of this report is to present a young patient with combined mitral valve and coronary artery disease to illustrate these challenges.In this report, we present a 47-year-old man with longstanding HIV infection who was referred with severe mitral regurgitation (MR) and profound...

متن کامل

Endocarditis after transcatheter aortic valve implantation: a current assessment

Transcatheter aortic valve implantation (TAVI) constitutes an established treatment in inoperable or high perioperative risk patients with severe aortic stenosis, demonstrating similar mortality rates (at 30 days and 1 year) with surgical aortic valve replacement (SAVR). Various complications have been reported during TAVI, weeks or months post procedure. The most frequent causes of transcathet...

متن کامل

Transcatheter aortic valve implantation

Transcatheter aortic valve implantation was developed to offer a therapeutic solution to patients with severe symptomatic aortic stenosis who are not candidates for conventional aortic valve replacement. The improvement in transcatheter aortic valve implantation outcomes is still of concern in the areas of stroke, vascular injury, heart block, paravalvular regurgitation and valve durability. Co...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Circulation. Cardiovascular interventions

دوره 9 9  شماره 

صفحات  -

تاریخ انتشار 2016